Early stage HER2-positive breast cancers not achieving a pCR from neoadjuvant trastuzumab-or pertuzumab-based regimens have an immunosuppressive …
Background Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete
response (pCR) in patients with HER2-positive (HER2+) breast cancer treated with
trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune-
modulating effects. Pre-and post-treatment immune biomarkers in cancers treated with
neoadjuvant TCH with or without P are lacking. In this study we quantified baseline and
changes in TILs, cluster of differentiation (CD) 4+, CD8+, FoxP3+, and PD-L1+ cells using …
response (pCR) in patients with HER2-positive (HER2+) breast cancer treated with
trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune-
modulating effects. Pre-and post-treatment immune biomarkers in cancers treated with
neoadjuvant TCH with or without P are lacking. In this study we quantified baseline and
changes in TILs, cluster of differentiation (CD) 4+, CD8+, FoxP3+, and PD-L1+ cells using …